Last reviewed · How we verify
Human pancreatic islet
At a glance
| Generic name | Human pancreatic islet |
|---|---|
| Sponsor | Ospedale San Raffaele |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye (PHASE1, PHASE2)
- Safety of ENC-201-CED ENCRT (PHASE1)
- Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes (PHASE1, PHASE2)
- Islet Transplantation in Patients With "Brittle" Type I Diabetes (NA)
- Islet Transplantation in Type 1 Diabetic Kidney Allograft (PHASE2)
- Allogenic Islet Cell Transplantation (PHASE1, PHASE2)
- Islet Cell Transplant for Type 1 Diabetes (PHASE2)
- Pancreatic Islet Transplantation to the Anterior Chamber of the Eye (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Human pancreatic islet CI brief — competitive landscape report
- Human pancreatic islet updates RSS · CI watch RSS
- Ospedale San Raffaele portfolio CI